<DOC>
	<DOCNO>NCT00763061</DOCNO>
	<brief_summary>To evaluate Intraocular Pressure ( IOP ) lower efficacy safety Travoprost 0.004 % compare Timolol 0.5 % patient open-angle glaucoma ( OAG ) ocular hypertension ( OH ) . The study structure parallel design . The patient receive treatment 12 week .</brief_summary>
	<brief_title>Travatan Versus Timoptic Treating Open-angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description>To evaluate IOP lower efficacy safety fo Travoprost 0.004 % compare Timolol 0.5 % patient open-angle glaucoma ( OAG ) ocular hypertension ( OH ) . The study structure parallel design . The patient receive treatment 12 week .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>≥18 year ; IOP=1630mmHg OH OAG visual file abnormality : 1 . ≥3 adjacent point 24 degree field side horizontal meridian , p &lt; 5 % prepapillary diameter plot , one must p &lt; 1 % , 2 . Glaucoma Hemifield Test outside normal limit , 3 . Corrected Pattern Standard Deviation p &lt; 5 % Previous damage anterior chamber angle ; ocular inflammation ocular surgery within past 3 month ; Best Corrected Visual Acuity ( logMAR ) &lt; 1.0 ; contact lens wearer ; severe central field loss ; uncontrolled cardiovascular , hepatic renal disease ; medication within past 1 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Glaucoma</keyword>
</DOC>